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BACKGROUND: Recent studies have suggested differing toxicity patterns for patients with prostate cancer who receive treatment
with 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), or proton beam therapy (PBT). METH-
ODS: The authors reviewed patient-reported outcomes data collected prospectively using validated instruments that assessed bowel
and urinary quality of life (QOL) for patients with localized prostate cancer who received 3DCRT (n ¼ 123), IMRT (n ¼ 153) or PBT (n
¼ 95). Clinically meaningful differences in mean QOL scores were defined as those exceeding half the standard deviation of the base-
line mean value. Changes from baseline were compared within groups at the first post-treatment follow-up (2-3 months from the
start of treatment) and at 12 months and 24 months. RESULTS: At the first post-treatment follow-up, patients who received 3DCRT
and IMRT, but not those who received PBT, reported a clinically meaningful decrement in bowel QOL. At 12 months and 24 months,
all 3 cohorts reported clinically meaningful decrements in bowel QOL. Patients who received IMRT reported clinically meaningful dec-
rements in the domains of urinary irritation/obstruction and incontinence at the first post-treatment follow-up. At 12 months, patients
who received PBT, but not those who received IMRT or 3DCRT, reported a clinically meaningful decrement in the urinary irritation/
obstruction domain. At 24 months, none of the 3 cohorts reported clinically meaningful changes in urinary QOL. CONCLUSIONS:
Patients who received 3DCRT, IMRT, or PBT reported distinct patterns of treatment-related QOL. Although the timing of toxicity var-
ied between the cohorts, patients reported similar modest QOL decrements in the bowel domain and minimal QOL decrements in
the urinary domains at 24 months. Prospective randomized trials are needed to further examine these differences. Cancer
2013;119:1729–35.VC 2013 American Cancer Society.
KEYWORDS: 3-dimensional conformal radiotherapy, intensity-modulated radiotherapy, patient reported outcomes, prostate cancer,
proton therapy, quality of life.
INTRODUCTION
Three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), and proton beam
therapy (PBT) are means of delivering high-dose radiation for localized prostate cancer with acceptable rates of acute and
late toxicities.1,2 IMRT and PBT are technically advanced forms of conformal radiotherapy that may achieve radiation
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dose escalation to the prostate while minimizing toxicity
to surrounding normal tissues, particularly the bladder
and rectum. IMRT is now the predominant form of
radiotherapy delivered for the treatment of prostate cancer
in the United States.3-5 National attention has focused on
IMRT and PBT because of increased costs and limited
available evidence to demonstrate reduced toxicity.6-9
Recent reports using linked tumor registry and
administrative claims data have suggested that PBT is
associated with greater bowel toxicity than IMRT.7,9
Those authors appropriately echoed calls by the Institute
of Medicine, National Cancer Institute, Centers for Med-
icare and Medicaid Services, and Agency for Healthcare
Research and Quality for a randomized trial to compare
the 2 modalities.6,10-12 The Massachusetts General Hos-
pital and the University of Pennsylvania, in collaboration
with the National Cancer Institute and other institutions,
have recently opened such a trial. To further inform the
current national debate, we report patient-reported qual-
ity-of-life (QOL) data for 3 contemporary cohorts that
received treatment with 3DCRT, IMRT, or PBT mono-
therapy, which have informed the design of this random-
ized trial.
MATERIALS AND METHODS
Patients and Treatments
We collected and examined the most current patient-
reported QOL data from 3 prospective cohort studies
involving patients with localized prostate cancer who
received radiation therapy without androgen-suppres-
sion therapy. The PBT cohort comprised 95 men who
received treatment at Massachusetts General Hospital
between August 2004 and December 2008 and were sur-
veyed at baseline and 3 months, 12 months, and 24
months from the start of treatment. The IMRT cohort
comprised 153 men who received treatment at 9 univer-
sity-affiliated hospitals comprising the Prostate Cancer
Outcomes and Satisfaction with Treatment Quality
Assessment (PROST-QA) Consortium between March
2003 and March 2006 and were surveyed at baseline and
2 months, 6 months, 12 months, and 24 months after
the start of treatment. The 3DCRT cohort comprised
123 men who received treatment at Harvard-affiliated
hospitals between June 1994 and August 2000 and were
surveyed at baseline and 3 months, 12 months, and 24
months after the start of treatment. Each study was
reviewed and approved by the institutional review board
for the participating site, and all participating patients
provided informed written consent.
Measurement of Patient-Reported Quality
of Life
Domain-specific QOL was assessed with the Prostate
Cancer Symptom Indices (PCSI) scale for the PBT and
3DCRT cohorts and with the Expanded Prostate Cancer
Index Composite (EPIC) instrument for the IMRT
cohort. The PCSI and EPIC are similar instruments that
measure prostate cancer treatment-related QOL.13,14
Both instruments contain domains that measure bowel/
rectal, urinary irritation/obstruction, and urinary inconti-
nence QOL, which were included in the current analysis.
The primary endpoints of this study were the mean
change in QOL scores from pretreatment to post-treat-
ment in the acute (eg, 2-3 months after treatment initia-
tion) and late (eg, 12-24 months post-treatment) time
periods. Change scores within cohorts were calculated
only for patients who reported data at baseline and at the
specified time point for a given domain. The PCSI scale
was inverted such that both instruments produced scores
from 0 to 100, with lower scores indicating worse func-
tion.15-17
Statistical Analysis
Cohort characteristics were compared using the Fisher
exact test or the Kruskal-Wallis test. Mean score changes
from baseline within treatment cohorts were analyzed
using a t test for paired data. To adjust for multiple pair-
wise comparisons, a 2-sided P value < .006 (eg, .05 for 9
comparisons) was considered significant, so that the over-
all Type 1 error was 0.05 for each QOL domain. For stat-
istically significant mean score changes from baseline,
clinically meaningful change was defined as a mean
change score exceeding half the standard deviation of the
baseline value.18 All calculations were performed using
SAS 9.2 (SAS, Cary, NC).
RESULTS
Patient characteristics are listed in Table 1. Patients in the
PBT cohort were younger than those in the IMRT or
3DCRT cohorts. A greater proportion of patients in the
IMRT cohort were black. The 3DCRT cohort had higher
baseline prostate-specific antigen values and included
more patients with clinical T2 and T3 disease than the
PBT or IMRT cohorts. Radiotherapy dose ranges were
from 66.4 to 79.2 Gy for the 3DCRT cohort, from 75.6
to 79.2 Gy for the IMRT cohort, and from 74.0 to 82.0
Gy (relative biologic effectiveness) for the PBT cohort.
Radiotherapy was delivered according to each center’s
preferred practice at 1.8 to 2.0 Gy per day. Planning target
volume margins were not explicitly mandated but were
typically 10 mm for the 3DCRT cohort and 5 to 10 mm
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(with 5-mm to 7-mm rectal margins) for the IMRT
cohort (personal communication with treating physicians
at the participating institutions). Patients in the PBT
cohort received treatment with 5-mmmargins.15
In the immediate post-treatment period (2 months
from the start of treatment for the IMRT cohort and 3
months for the 3DCRT and PBT cohorts), patients in the
IMRT and 3DCRT cohorts, but not in the PBT cohort,
reported a clinically meaningful decrement in bowel/rec-
tal QOL (Fig. 1, Table 2). At 12 months and 24 months,
patients from all 3 cohorts reported clinically meaningful
decrements in bowel QOL.
In the immediate post-treatment period, patients in
the IMRT cohort reported clinically meaningful decre-
ments in QOL in the urinary irritation/obstruction and
urinary incontinence domains that were not observed in
the other 2 cohorts. At 12 months, only patients in the
PBT cohort reported clinically meaningful score decre-
ments in the urinary irritation/obstruction domain. At 24
months, clinically meaningful changes in urinary QOL
were not observed in any of the cohorts.
DISCUSSION
We undertook this study to present the best available evi-
dence examining prospective patient-reported outcomes
before and after treatment with 3DCRT, IMRT, or PBT
for localized prostate cancer. We observed that, in the
acute setting after radiotherapy, 3DCRT and IMRT were
associated with modest but clinically meaningful reduc-
tions in bowel and/or urinary QOL. This same pattern
was not observed in patients who received PBT. At 24
months, patients who received all 3 radiation modalities
reported modest but clinically meaningful changes in
bowel QOL.
These data are consistent with and extend previously
published patient-reported and physician-reported toxicity
and QOL studies after external-beam radiotherapy for pros-
tate cancer.15-17,19-24 Although it has been suggested that
IMRT reduces bowel toxicity compared to 3DCRT, recent
cohort studies comparing these 2 modalities demonstrated
no clear differences in patient-reported outcomes.3,25,26
Late bowel toxicity has been correlated with the vol-
ume of rectum receiving specific doses of radiotherapy;
TABLE 1. Characteristics of Patients who Received 3-Dimensional Conformal Radiotherapy, Intensity-
Modulated Radiotherapy, and Proton Beam Therapy
No. of Patients (%)
Characteristic PBT IMRT 3DCRT Pa
Total no. of patients 95 153 123
Enrollment period 2004-2008 2003-2006 1994-2000
Age: Median [Range] y 64 [49-78] 69 [47-83] 70 [54-82] < .001
Race < .001
White 87 (93) 121 (79) 116 (94)
Black 6 (6) 27 (18) 2 (2)
Other 1 (1) 2 (1) 1 (1)
Missing 1 (1) 3 (2) 4 (3)
Marriage status .20
Married or cohabiting 72 (77) 124 (81) 105 (85)
Other 22 (23) 29 (19) 15 (12)
Missing 1 (1) 0 3 (2)
Education level .14
College graduate 60 (64) 77 (50) 67 (54)
Other 34 (36) 76 (50) 53 (43)
Missing 1 (1) 0 3 (2)
PSA: Median [range], ng/mL 5.2 [2.3-15] 5.8 [0.5-25.8] 7.5 [0.9-77.4] < .001
Clinical tumor classification < .001
T1 75 (80) 123 (80) 49 (40)
T2 19 (20) 30 (20) 63 (51)
T3 0 0 7 (6)
Missing 1 (1) 0 4 (3)
Gleason score .53
4-6 63 (67) 97 (63) 66 (54)
7 30 (32) 56 (37) 38 (31)
8-10 1 (1) 0 15 (12)
Missing 1 (1) 0 4 (3)
Abbreviations: 3DCRT, 3-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; PBT, proton beam therapy; PSA, prostate-specific
antigen.
aP values were calculated for comparisons across all 3 cohorts.
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however, acute bowel toxicity after radiotherapy is less
studied.27,28 We observed that PBT was not associated
with a clinically meaningful decrement in bowel QOL in
the acute period after radiation. Assuming equal prescrip-
tion doses and target margins, PBT reduces low-dose radi-
ation exposure to the whole rectum and delivers high
doses (similar to 3DCRT and IMRT) along the small
strip of the anterior rectal wall immediately posterior to
the prostate.29,30 IMRT in particular is associated with a
low-dose radiation bath over a larger pelvic area; and its
effects may be an important driver of acute bowel toxicity.
This hypothesis is supported by data indicating that inter-
mediate-dose rectal exposure or mean rectal dose is a bet-
ter predictor of acute bowel toxicity than the absolute
dose delivered to the prostate (and, thus, received by the
nearby anterior rectal wall).31-33 Acute bowel toxicity also
may predict for higher late toxicity, such as rectal bleed-
ing.34 Furthermore, data also suggest that rectal volumes
receiving intermediate doses of radiotherapy are the best
predictors of late toxicity.35-37 Other researchers, how-
ever, have published data to suggest that the volume of
rectum exposed to the highest doses of radiation (ie, 70
Gy) is the strongest predictor of late toxicity and that such
toxicity in fact may be independent of the prescription
Figure 1. Longitudinal patient-reported mean quality-of-life scores are illustrated for patients with prostate cancer who received
(A) proton beam therapy (PBT), (B) intensity-modulated radiotherapy (IMRT), or (C) 3-dimensional conformal radiotherapy
(3DCRT) in the bowel/rectal, urinary irritation/obstruction, and urinary incontinence domains. Error bars represent 95% confi-
dence intervals. N indicates the number of patients reporting data at the given time point.
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dose.38-40 Given this lack of consensus, further prospec-
tive studies are needed to address this issue.
In the acute setting, IMRT also was associated with
modest but clinically meaningful changes in the urinary
irritation/obstruction and incontinence domains while
similar decrements were not seen in the PBT cohort. A
similar early but time-limited benefit for PBT was also
noted in a recent comparison of Medicare claims data.41
One possible contributor is that IMRT may produce
small radiation ‘‘hot spots,’’ which exceed the prescribed
radiation dose by up to 15% within the prostate and/or
prostatic urethra (which are not typically observed with
3DCRT or PBT).29 Although patients in the 3DCRT
cohort did not report significant urinary QOL decre-
ments, lower radiation doses may have mitigated symp-
toms in this group. Patients in the PBT cohort reported
clinically meaningful urinary toxicity at 12 months, a pat-
tern not observed in the other 2 cohorts. Differential
treatment dose also may have contributed to this finding
because many patients in the PBT cohort received doses
of 82 gray equivalent (GyE), which has been shown to
increase urinary toxicity compared with doses of 78 to 79
Gy.2 However, we observed no clinically meaningful score
decrements in urinary QOL in any of our 3 cohorts at 24
months, suggesting that, although these symptoms may
vary in their onset, typically, they are transient.
Our findings differ from those in 2 recent reports
that examined bowel and urinary complications after
radiotherapy using the linked Surveillance, Epidemiology,
and End Results-Medicare database.7,9 Both studies iden-
tified radiotherapy complications based on billing claims
for diagnoses and procedures and observed increased
bowel toxicity in patients who received PBT compared
with IMRT or 3DCRT. Medicare codes are a coarse mea-
sure of treatment complications, insensitive to patient
symptoms, and subject to both confounding and misclas-
sification bias.3,42 Furthermore, those studies did not col-
lect or report information on radiation dose, target
margins, or dose-volume histogram characteristics, which
may have varied significantly between groups. In addition,
Kim et al reported significantly lower gastrointestinal tox-
icity among patients who received treatment during the
last 2 years of their analyzed PBT cohort, suggesting that a
learning curve for this advanced technology may be pres-
ent. Nonetheless, those studies presented important and
complementary views of these modalities, highlighting
the need for a randomized trial.7
Our study has several limitations. Although we pres-
ent updated, prospectively collected data for each cohort,
the nonrandomized design and significant differencesTA
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between the baseline characteristics of the cohorts pre-
clude a direct statistical comparison of QOL outcomes
between groups. In addition, data for patients were col-
lected using 2 different validated instruments. Although
these instruments measure outcomes in a similar way
across the analyzed domains, subtle differences in ques-
tion wording may affect patient responses.17,23,43 To par-
tially overcome this limitation, we defined a clinically
meaningful score change as a score that exceeded half the
standard deviation of the baseline value. This approach
provides a more standardized measure across QOL
instruments.18
The patients in our study were treated according to
the standard practice at each center, including the selec-
tion of dose, target margins, and normal tissue con-
straints, as noted above. Given the similar relative biologic
effectiveness of protons and photons, it is likely that any
differences in toxicity between the techniques relate to dif-
ferences in dose-volume factors, although underlying
radiobiologic differences cannot be ruled out. However,
because different target margins and doses were used in
the 3 cohorts, it is difficult to disentangle the relative con-
tribution of these factors from the potential benefits of a
given treatment modality.
Our data also are limited by a 1-month difference in
survey delivery between the cohorts measured by the
PCSI and EPIC instruments. This difference may intro-
duce bias into the interpretation of toxicity in the acute
setting, because patients may report greater toxicity closer
to treatment. Although this may be the case, at least 1
study has suggested that many of the effects on the bowel
associated with pelvic radiotherapy are present with simi-
lar intensity 2 months after treatment relative to 2
weeks.44 Furthermore, because the patients in our study
who received 3DCRT reported significant decrements in
their bowel QOL score at 3 months (despite lower treat-
ment doses), both 2 months and 3 months after the start
of therapy appear to be reasonable times to assess such tox-
icity. Finally, substantially fewer patients in our PBT
cohort returned their 24-month questionnaire relative to
the other cohorts, which may have introduced sampling
bias.
Patient experience of treatment-associated morbid-
ity is complex and likely is influenced by numerous fac-
tors, including radiation dose, target margins, dose-
volume histogram characteristics, data-collection meth-
ods, and perhaps treatment modality. Given the limita-
tions in the available evidence and the potential promise
but expense of PBT, a carefully designed randomized con-
trolled trial that accounts for all of these issues presents an
important opportunity to examine the comparative
effectiveness of PBT before its widespread adoption and
diffusion. Although, to our knowledge, there are no
randomized data to suggest that 3DCRT is an inferior
modality, currently, it is rarely used in the United States.
Therefore, the recently launched trial will randomize men
with localized prostate cancer to receive either PBT or
IMRT and will follow them longitudinally to assess subse-
quent patient-reported bowel, urinary, and erectile func-
tion. Health state utilities and economic endpoints also
will be measured.We have observed that nearly 60% of el-
igible patients state they are likely to enroll in such a
trial.45 The results of this trial will provide patients, clini-
cians, payers, and policy makers with the most valid com-
parison of modern radiation-based technologies for the
treatment of localized prostate cancer.
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